B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.

ABSTRACT:

Background

Natriuretic peptides are substrates of neprilysin; hence, B-type natriuretic peptide (BNP) concentrations rise with neprilysin inhibition. Thus, the clinical validity of measuring BNP in sacubitril/valsartan-treated patients has been questioned, and use of N-terminal pro-B-type natriuretic peptides (NT-proBNP) has been preferred and recommended.

Objectives

The purpose of this study was to determine the prognostic performance of BNP measurements before and during treatment with sacubitril/valsartan.

Methods

BNP and NT-proBNP were measured before and after 4 to 6 weeks, 8 to 10 weeks, and 9 months of treatment with sacubitril/valsartan in the PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart F

SUBMITTER: Myhre PL 

PROVIDER: S-EPMC7955687 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature